Scarica l'app Stockscreener
24.43
1.88%
0.45
Pre-mercato:
24.49
0.06
+0.25%
Pulse Biosciences Inc Borsa (PLSE) Ultime notizie
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story - Yahoo Finance
Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network
Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus
Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Business Wire
Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView
Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18Asset Allocation - Xã Vĩnh Công
Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat
Pulse Biosciences to Host Analyst Event on April 25, 2026 - The Joplin Globe
PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill
Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks
Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks
Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView
Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan
Trading Systems Reacting to (PLSE) Volatility - Stock Traders Daily
Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Income Plays: Does Pulse Biosciences Inc have strong fundamentalsPortfolio Update Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - Yahoo Finance
Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - Sahm
Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance
Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus
Pulse Biosciences hires Liane Teplitsky as COO - MedTech Dive
Pulse Biosciences names Liane Teplitsky as chief operating officer By Investing.com - Investing.com Australia
Pulse Biosciences, Inc. (PLSE) stock price, news, quote and history - Yahoo Finance Singapore
Pulse Biosciences Strengthens Executive Leadership Team - Investing News Network
Pulse Biosciences appoints new COO to advance commercialization - TipRanks
Pulse Biosciences Appoints Liane Teplitsky as Chief Operating Officer Effective April 8, 2026 - Minichart
Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences - TradingView
Pulse Biosciences (PLSE) hires new COO with large inducement equity grants - Stock Titan
Pulse Biosciences Names Liane Teplitsky Chief Operating Officer - marketscreener.com
Pulse Biosciences strengthens executive leadership team - marketscreener.com
Pulse Biosciences names Liane Teplitsky as chief operating officer - Investing.com
Pulse Biosciences: Promising Catheter Technology, Weak Risk-Reward For Now - Seeking Alpha
How Low Can PLSE Really Go In A Market Crash? - Trefis
Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock - Trefis
Pulse Biosciences Inc Enrolls First Patients in NANOPULSE-AF Ide Pivotal Clinical Study Evaluating nsPFA Cardiac Catheter System for Atrial Fibrillation - marketscreener.com
Pulse Biosciences Enrolls 1st Patient in nPulse PFA Tech Trial for AFib - Medical Product Outsourcing
Pulse Biosciences Inc (PLSE) Shares Gap Down to $19.14 on Apr 7 - GuruFocus
Pulse Biosciences begins pivotal atrial fibrillation trial By Investing.com - Investing.com South Africa
Pulse Biosciences Launches Pivotal NANOPULSE-AF Clinical Study - TipRanks
Pulse Biosciences, Inc. Files 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
First patients treated in Pulse Biosciences (NASDAQ: PLSE) NANOPULSE-AF AFib trial - Stock Titan
Pulse Biosciences begins pivotal atrial fibrillation trial - Investing.com
Pulse Biosciences (NASDAQ: PLSE) recently announced that its pivotal clinical study of the Npulse™ Cardiac Catheter System for atrial fibrillation treatment (Nanopulse-Af Ide) has completed enrollment of the first group of patients. - Bitget
Pulse Biosciences enrolls first patients in Nanopulse-AF IDE pivotal clinical study evaluating nPulse(TM) cardiac catheter system for atrial fibrillation - marketscreener.com
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation - TradingView — Track All Markets
PLSE SEC FilingsPulse Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
0.97%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):